{"abstract": "In the search for a new money-maker Pfizer paid $195 million for Houston-based Encysive Pharmaceuticals, a small outfit with big hopes for a breakthrough drug that, so far, the Food and Drug Administration has snubbed.", "web_url": "https://dealbook.nytimes.com/2008/02/21/looking-for-next-big-hit-pfizer-spends-195-million-on-encysive/", "snippet": "", "lead_paragraph": "In the search for a new money-maker Pfizer paid $195 million for Houston-based Encysive Pharmaceuticals, a small outfit with big hopes for a breakthrough drug that, so far, the Food and Drug Administration has snubbed.", "source": "The New York Times", "multimedia": [], "headline": {"main": "Looking for Next Big Hit, Pfizer Spends $195 Million on Encysive", "kicker": "DealBook", "content_kicker": null, "print_headline": "", "name": null, "seo": null, "sub": null}, "keywords": [], "pub_date": "2008-02-21T11:42:41+0000", "document_type": "article", "news_desk": "Business", "section_name": "Business Day", "byline": {"original": "By Dealbook", "person": [{"firstname": "Dealbook", "middlename": null, "lastname": "", "qualifier": null, "title": null, "role": "reported", "organization": "", "rank": 1}], "organization": null}, "type_of_material": "News", "_id": "nyt://article/92c051f1-43a5-5cc8-aad4-7d4e34e20323", "word_count": 154, "uri": "nyt://article/92c051f1-43a5-5cc8-aad4-7d4e34e20323"}